Efficacy and proarrhythmia with the use of d,l-sotalol for sustained ventricular tachyarrhythmias

Journal of Cardiovascular Pharmacology

Volumn 29, Issue 3, 1997, Pages 373-381

  Kühlkamp, Volker ^a,b   Mermi, Johannes ^a   Mewis, Christian ^a   Seipel, Ludger ^a  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

d,l Sotalol; Electrophysiology; QT interval; QTc interval; Risk factors for torsades de pointes; Torsades de pointes

Indexed keywords

SOTALOL;

ADULT; AGED; ARRHYTHMOGENESIS; ARTICLE; BRADYCARDIA; CLINICAL PROTOCOL; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DRUG EFFICACY; ELECTROCARDIOGRAPHY MONITORING; ELECTROSTIMULATION; FEMALE; HEART DILATATION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; HYPOTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; QT INTERVAL; RISK FACTOR; TORSADE DES POINTES; VERTIGO;

ADULT; ANTI-ARRHYTHMIA AGENTS; ELECTROCARDIOGRAPHY; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; SOTALOL; TACHYCARDIA, VENTRICULAR; TORSADES DE POINTES; VENTRICULAR FIBRILLATION;

EID: 0343907254     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-199703000-00011     Document Type: Article

References (34)

1. Singh BN, Vaughan Williams EM. A third class of antiarrhythmic action: effects on atrial and ventricular action potentials and other pharmacologic actions on cardiac muscle, of MJ 1999 and AH 3474. Br J Pharmacol 1970;39;675-87.
2. Mason JW. A comparison of seven antiarrhythmic drugs in patients with ventricular tachyarrhythmias. N Engl J Med 1993;329:452-8.
3. Wellens HJJ, Smeets JL, Vos M, Gorgels AP. Antiarrhythmic drug treatment: need for continuous vigilance. Br Heart J 1992;67: 25-33.
4. Kehoe RF, McNeil DJ, Zheutlin TA, et al. Safety and efficacy of oral sotalol for sustained ventricular tachyarrhythmias refractory to other antiarrhythmic agents. Am J Cardiol 1993;72(suppl):56-66A.
5. Lepeschkin E, Surawicz B. The measurement of the Q-T interval of the electrocardiogram. Circulation 1952;6:378-88.
6. Martin AB, Perry JC, Robinson JL, Zareba W, Moss AJ, Garson A. Calculation of QTc duration and variability in the presence of sinus arrhythmia. Am J Cardiol 1995;75:950-3.
7. Molnar J, Weiss JS, Rosenthal JE. The missing second: what is the correct unit for the Bazett corrected QT interval? Am J Cardiol 1995;75:537-8.
8. Kehoe RF, Zheutlin TA, Dunnington CS, Mattioni TA, Yu G, Spangenberg RB. Safety and efficacy of sotalol in patients with drug-refractory sustained ventricular tachyarrhythmias. Am Heart J 1990; 65(suppl):58-64A.
9. Ruder MA, Ellis T, Lebsack C, Mead RH, Smith NA, Winkle RA. Clinical experience with sotalol in patients with drug refractory ventricular arrhythmias. J Am Coll Cardiol 1989;13:145-52.
10. Kuchar DL, Garan H, Venditti FJ, et al. Usefulness of sotalol in suppressing ventricular tachycardia or ventricular fibrillation in patients with healed myocardial infarcts. Am Heart J 1989;64: 33-6.
11. Gonzalez R, Scheinman MM, Herre JM, Griffin JC, Sauve MJ, Sharkey H. Usefulness of sotalol for drug-refractory malignant ventricular arrhythmias. J Am Coll Cardiol 1988;12:1568-72.
12. Singh SN, Cohen A, Chen Y, et al. Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest. Am Heart J 1988;62:399-402.
13. Borggrefe M, Haverkamp W, Shenasa M, Hindricks G, Breithardt G. How to evaluate class III antiarrhythmic drug efficacy clinically: the benefits and shortcomings of the invasive approach. J Cardiovasc Pharmacol 1992;20(suppl 1):32-40.
14. Singh BN, Kehoe RF, Woosley RL, Scheinman MM, Quart B. Multicenter trial of sotalol compared with procainamide in the suppression of inducible ventricular tacchycardia: a double blind, randomized parallel evaluation. Am Heart J 1995;129:87-97.
15. Senges J, Lengfelder W, Jauering R, et al. Electrophysiologic testing in assessment of therapy with sotalol for sustained ventricular tachycardia. Circulation 1984;69:577-84.
16. Nademanee K, Feld G, Hendrickson J, Singh PN, Singh BN. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias. Circulation 1985;72: 555-64.
17. Hinkle LE, Thaler HT. Clinical classification of cardiac death. Circulation 1982;65:457-64.
18. Jordaens LJ, Palmer A, Clement DL. Low-dose oral sotalol for monomorphic ventricular tachycardia: effects during programmed electrical stimulation and follow-up. Eur Heart J 1989;10:218-26.
19. Kienzle MG, Martins JB, Wendt DJ, Constantin L, Hopson R, McCue ML. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs. Am Heart J 1988;561:1012-7.
20. Kus T, Campa MA, Nadeau R, Dubuc M, Kaltenbrunner W, Shenasa M. Efficacy and electrophysiologic effects of oral sotalol in patients with sustained ventricular tachycardia caused by coronary artery disease. Am Heart J 1992;123:82-9.
21. Kühlkamp V, Mermi J, Szendey I, et al. Long term efficacy of d/l-sotalol in patients with drug refractory ventricular tachyarrhythmias and an implantable cardioverter defibrillator. Circulation 1992;86(suppl I):1-533.
22. Steinbeck G, Andresen D, Bach P, et al. A comparison of electrophysiologically guided antiarrhythmic therapy with beta-blocker therapy in patients with symptomatic, sustained ventricular tachyarrhythmias. N Engl J Med 1992;327:987-92.
23. Waldo AL, Camm AJ, de Ryuter H, et al. Preliminary mortality results from the Survival with Oral D-Sotalol (SWORD) trial [Abstract]. J Am Coll Cardiol 1995;25(suppl):15A.
24. Seidl K, Hauer B, Schilling I, Senges J. Vergleich zwischen Häufigkeit von Arrhythmierezidiven bei ICD Patienten in Abhängigkeit der Begleitmedikation: Sotalol vs. Metoprolol [Abstract]. Z Kardiol 1994;83(suppl I):195.
25. Antz M, Cappato R, Kuck KH. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia. J Cardiovasc Pharmacol 1995;26:627-35.
26. Julian DG, Prescott RJ, Jackson FS, Szekely P. Controlled trial of sotalol for one year after myocardial infarction. Lancet 1982;1142-7.
27. Thompson KA, Murray JJ, Blaier IA, Woosley RL, Roden DM. Plasma concentrations of quinidine, its major metabolites, and dihydroquinidine in patients with torsades de pointes. Clin Pharmacol Ther 1988;43:636-42.
28. McNeil DJ, Davies RO, Deitchman D. Clinical safety profile of sotalol in the treatment of arrhythmias. Am J Cardiol 1993;72:44-50A.
29. Hohnloser S, Arendts W, Quart B. Incidence, type and dose dependence of proarrhythmic events during sotalol therapy in patients treated for sustained VT/VF [Abstract]. PACE Pacing Clin Electrophysiol 1992;15:551.
30. Pratt CM, Greenway PS, Schoenfeld MH, Hibben ML, Reiffel JA. Explorations of the precision of classifying sudden cardiac death: implications for the interpretation of clinical trials. Circulation 1996;93:519-24.
31. Funck-Brentano C, Kibleur Y, Le Coz F, Poirier J-M, Mallett A, Jailon P. Rate dependence of sotalol induced prolongation of ventricular repolarization during exercise in humans. Circulation 1991;83: 536-45.
32. Makkar RR, Fromm BS, Steinman RT, Meissner MD, Lehman MH. Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs. JAMA 1993;270:2590-7.
33. Kadish AH, Weisman HF, Veltri EP, Epstein AE, Slepian MJ, Levine JH. Paradoxical effects of exercise on the QT interval in patients with polymorphic ventricular tachycardia receiving type Ia antiarrhythmic agents. Circulation 1990;81:14-9.
34. Kühlkamp V, Mermi J, Seipel L. Torsades de pointes with d/l-sotalol in patients with supraventricular and ventricular tachyarrhythmias [Abstract]. Circulation 1993;88(suppl):2392.